Compare AMR & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMR | MLYS |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.1B |
| IPO Year | N/A | 2023 |
| Metric | AMR | MLYS |
|---|---|---|
| Price | $243.22 | $32.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $168.00 | $47.33 |
| AVG Volume (30 Days) | 249.8K | ★ 1.5M |
| Earning Date | 02-27-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,226,356,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.39 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $97.41 | $8.24 |
| 52 Week High | $253.82 | $47.65 |
| Indicator | AMR | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 68.87 | 33.20 |
| Support Level | $230.99 | $31.67 |
| Resistance Level | $253.82 | $33.64 |
| Average True Range (ATR) | 12.37 | 1.67 |
| MACD | 2.22 | -0.23 |
| Stochastic Oscillator | 78.46 | 19.56 |
Alpha Metallurgical Resources Inc is a Tennessee-based coal mining company with operations across Virginia and West Virginia. The company's portfolio of mining operations consists of underground mines, surface mines, and coal preparation plants. It produces low-ash metallurgical coal, including High-Vol. A, Mid-Vol., High-Vol. B, and Low-Vol. coal, which is shipped to domestic and international coke and steel producers. The reportable segment of the company is Met. It extracts, processes and markets met and thermal coal from deep and surface mines for sale to steel and coke producers, industrial customers, and electric utilities.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.